Performance Support
Muscle Growth & Anabolism Research Discussion
Advanced educational protocol for compounds studied in skeletal muscle hypertrophy and anabolic signaling research
• This protocol is provided for educational and informational purposes only. It does not constitute medical advice, a diagnosis, a treatment plan, or a prescription.
• All dose ranges, frequencies, durations, and compound selections must be determined by a licensed healthcare professional based on your individual medical history, lab results, and clinical assessment.
• Lab monitoring may be required depending on the compound(s), individual health status, and duration of use. Discuss appropriate monitoring protocols with your clinician.
• Do not use any peptide compound if you are pregnant, breastfeeding, a minor, or have uncontrolled medical conditions without explicit direction from your physician.
High Risk — Specialist Supervision Required
Significant safety considerations; not suitable for unsupervised use
Overview
This advanced educational protocol covers research discussion points for compounds studied in skeletal muscle hypertrophy, anabolic signalling, and myogenic satellite cell activation. These compounds carry HIGH RISK designations due to their potency, limited human safety data, and theoretical oncological concerns. Specialist physician oversight is mandatory for any clinical consideration.
Mechanism Summary
IGF-1 LR3 is a modified IGF-1 analogue with a 13-amino acid extension that reduces binding affinity for IGF-binding proteins, extending its half-life. It signals through the IGF-1 receptor (IGF-1R) to activate PI3K/Akt/mTOR and MAPK/ERK pathways driving protein synthesis and satellite cell proliferation. MGF (Mechano Growth Factor) is a splice variant of IGF-1 generated locally in muscle in response to mechanical load, studied for satellite cell activation. PEGylation extends its systemic half-life for research use. Follistatin is an activin-binding glycoprotein that neutralises myostatin (GDF-8) and activin signalling, disinhibiting skeletal muscle growth pathways.
Intended Goal
Prepare for a specialist clinician consultation on peptide compounds studied in skeletal muscle anabolism and myogenic signaling research
IGF-1 LR3
IGF-1 analogue / myogenic / anabolic signaling
Long-acting IGF-1 analogue with extended serum half-life. Studied for myogenic and anabolic signaling in research contexts. High risk — requires specialist oversight. Catalog reference.
PEG-MGF
Mechano Growth Factor / myogenic / satellite cell activation
PEGylated mechano growth factor isoform. Studied for local muscle repair and satellite cell activation. Experimental. Catalog reference.
Follistatin 344
Myostatin inhibitor / anabolic / muscle hypertrophy
Activin-binding protein that inhibits myostatin signalling. Studied for potential muscle hypertrophy in research. Very limited human data. Catalog reference.
Research reference values only. Confirm all parameters with current literature and your clinician.
Who may be a candidate
- ✓Adults with clinician-confirmed muscle wasting conditions under specialist care
- ✓Researchers or clinical investigators operating within approved research protocols
- ✓Highly experienced individuals under specialist endocrinology or sports medicine supervision
Exclusions
- ✕Not appropriate for healthy adults seeking aesthetic muscle gain without medical necessity
- ✕Not appropriate without specialist physician supervision
- ✕Not appropriate for individuals under 25 (open growth plates)
- ✕Not appropriate for individuals with personal or family history of cancer (IGF-axis concern)
Is my IGF-1 level within range and are there concerns about adding further IGF-axis stimulation?
Am I a candidate for any of these compounds given my oncological risk profile?
What glucose monitoring protocol would you recommend with IGF-1 LR3?
How do you evaluate myostatin inhibition compounds in a clinical context?
Print or copy these questions using the "Copy Summary" button to bring to your appointment.
Legal & Compliance Notice
IGF-1 LR3, PEG-MGF, and Follistatin 344 are research chemicals not approved for therapeutic use in most jurisdictions. Any use outside of licensed clinical research is subject to significant regulatory risk.
The legal and regulatory status of research compounds varies by country and jurisdiction. It is the user's responsibility to understand applicable local laws before engaging with any compound.
This application does not provide personalized dosing recommendations. Users who require medical guidance should consult a qualified clinician.
Last reviewed: 2025-03-01 · Status: reviewed
Discuss with Your Clinician
Use this protocol as a research starting point. A qualified healthcare professional can review your health history, order appropriate labs, and help you determine what approach — if any — makes sense for your specific situation.